Log in

NASDAQ:ATXIAvenue Therapeutics Stock Price, Forecast & News

$8.50
-0.39 (-4.39 %)
(As of 04/7/2020 08:30 AM ET)
Add
Compare
Today's Range
$8.39
Now: $8.50
$9.13
50-Day Range
$6.44
MA: $8.36
$10.50
52-Week Range
$4.13
Now: $8.50
$11.47
Volume64,962 shs
Average Volume70,287 shs
Market Capitalization$141.78 million
P/E RatioN/A
Dividend YieldN/A
Beta0.08
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York.
Read More
Avenue Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.99 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATXI
CUSIPN/A
Phone781-652-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.41 per share

Profitability

Net Income$-25,910,000.00

Miscellaneous

Employees6
Market Cap$141.78 million
Next Earnings Date5/11/2020 (Estimated)
OptionableNot Optionable

Receive ATXI News and Ratings via Email

Sign-up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.


Avenue Therapeutics (NASDAQ:ATXI) Frequently Asked Questions

How has Avenue Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Avenue Therapeutics' stock was trading at $7.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ATXI stock has increased by 14.2% and is now trading at $8.50. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Avenue Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avenue Therapeutics.

When is Avenue Therapeutics' next earnings date?

Avenue Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Avenue Therapeutics.

How were Avenue Therapeutics' earnings last quarter?

Avenue Therapeutics Inc (NASDAQ:ATXI) posted its quarterly earnings data on Monday, March, 30th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.29) by $0.04. View Avenue Therapeutics' earnings history.

What price target have analysts set for ATXI?

1 analysts have issued 1 year target prices for Avenue Therapeutics' shares. Their forecasts range from $12.00 to $12.00. On average, they expect Avenue Therapeutics' share price to reach $12.00 in the next year. This suggests a possible upside of 41.2% from the stock's current price. View analysts' price targets for Avenue Therapeutics.

Has Avenue Therapeutics been receiving favorable news coverage?

Media coverage about ATXI stock has been trending very negative on Tuesday, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Avenue Therapeutics earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutAvenue Therapeutics.

Are investors shorting Avenue Therapeutics?

Avenue Therapeutics saw a decline in short interest in March. As of March 13th, there was short interest totaling 4,600 shares, a decline of 59.3% from the February 27th total of 11,300 shares. Based on an average daily trading volume, of 71,700 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.1% of the shares of the stock are sold short. View Avenue Therapeutics' Current Options Chain.

Who are some of Avenue Therapeutics' key competitors?

What other stocks do shareholders of Avenue Therapeutics own?

Who are Avenue Therapeutics' key executives?

Avenue Therapeutics' management team includes the following people:
  • Dr. Lindsay Allan Rosenwald, Exec. Chairman (Age 64)
  • Dr. Lucy Lu, Pres, CEO & Director (Age 44)
  • Mr. Joseph Walter Vazzano, CFO, Principal Financial Officer & Company Sec. (Age 35)
  • Dr. Scott A. Reines, Interim Chief Medical Officer (Age 72)

When did Avenue Therapeutics IPO?

(ATXI) raised $30 million in an initial public offering on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer served as the underwriter for the IPO and National Securities Corp. was co-manager.

What is Avenue Therapeutics' stock symbol?

Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."

How do I buy shares of Avenue Therapeutics?

Shares of ATXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avenue Therapeutics' stock price today?

One share of ATXI stock can currently be purchased for approximately $8.50.

How big of a company is Avenue Therapeutics?

Avenue Therapeutics has a market capitalization of $141.78 million. The company earns $-25,910,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Avenue Therapeutics employs 6 workers across the globe. View additional information about Avenue Therapeutics.

What is Avenue Therapeutics' official website?

The official website for Avenue Therapeutics is http://www.avenuetx.com/.

How can I contact Avenue Therapeutics?

Avenue Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel